Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diphenoxylate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 8/20 | 0.98 |
| ▸ | KCNA3 | P22001 | 5/20 | 0.98 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.65 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diphenoxylate SCHEMBL42940 | 0.99 | OPRM1 (1.00) | OPRM1KCNA3OPRD1OPRK1SLC22A1 | |
| Diphenoxylate SCHEMBL20595320 | 0.98 | OPRM1 (0.98) | OPRM1KCNA3OPRD1OPRK1SLC22A1 | |
| Diphenoxylate SCHEMBL28385054 | 0.98 | OPRM1 (0.98) | OPRM1KCNA3OPRD1OPRK1SLC22A1 | |
| Diphenoxylate SCHEMBL28374697 | 0.98 | OPRM1 (0.98) | OPRM1KCNA3OPRD1OPRK1SLC22A1 | |
| Diphenoxylate SCHEMBL28596518 | 0.98 | OPRM1 (0.98) | OPRM1KCNA3OPRD1OPRK1SLC22A1 | |
| Diphenoxylate SCHEMBL8160138 | 0.96 | OPRM1 (0.94) | OPRM1KCNA3OPRD1OPRK1SLC22A1 | |
| Diphenoxylate SCHEMBL3083175 | 0.96 | OPRM1 (0.94) | OPRM1KCNA3OPRD1OPRK1SLC22A1 | |
| Diphenoxylate SCHEMBL29019114 | 0.91 | OPRM1 (0.84) | OPRM1KCNA3OPRD1OPRK1SLC22A1 | |
| Hydrochloric Acid SCHEMBL11600368 | 0.91 | OPRM1 (0.81) | OPRM1KCNA3OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL11607175 | 0.90 | KCNA3 (0.80) | OPRM1KCNA3OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1674 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4232004-A1 | FRACTAL FORMULATIONS | Nanogyre Sprl (BE) | 2023-08-30 | — | — | EP | claimed |
| US-20230248734-A1 | ANTIVIRAL COMPOSITION OBTAINED THROUGH DRUG REPOSITIONING | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2023-08-10 | — | — | US | claimed |
| CN-112375030-B | Preparation method of diphenoxylate hydrochloride | 常州康普药业有限公司 | 2023-02-03 | — | — | CN | claimed |
| CN-108904457-B | Compound diphenoxylate tablet and preparation method thereof | 河北君圣药业有限公司 | 2021-07-20 | — | — | CN | claimed |
| US-11033572-B2 | Molecular adjuvants for enhanced cytosolic delivery of active agents | UNIVERSITEIT GENT (BE) | 2021-06-15 | — | — | US | claimed |
| WO-2021078412-A1 | FRACTAL FORMULATIONS | MESSADEK JALLAL (BE) | 2021-04-29 | — | — | WO | claimed |
| CN-110522726-B | Preparation method of dipheny hydrochloride liposome and dipheny hydrochloride liposome | 齐齐哈尔医学院 | 2021-04-20 | — | — | CN | claimed |
| CN-112375030-A | Preparation method of diphenoxylate hydrochloride | 常州康普药业有限公司 | 2021-02-19 | — | — | CN | claimed |
| US-20200147076-A1 | PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | PLATFORM BRIGHTWORKS TWO, LTD. (US) | 2020-05-14 | — | — | US | claimed |
| CN-104857515-B | Drug core composition for controlled release drug delivery and osmotic pump preparation containing the same | 中国科学院上海药物研究所 | 2020-01-10 | — | — | CN | claimed |
| WO-2001054481-A2 | ENHANCED PROPERTIED PHARMACEUTICALS | ROHM AND HAAS COMPANY (US) | 2001-08-02 | — | — | WO | claimed |
| EP-1119345-A1 | ENCAPSULATION OF SENSITIVE LIQUID COMPONENTS INTO A MATRIX TO OBTAIN DISCRETE SHELF-STABLE PARTICLES | GENERAL MILLS, INC. (US) | 2001-08-01 | — | — | EP | claimed |
| WO-2000021504-A1 | ENCAPSULATION OF SENSITIVE LIQUID COMPONENTS INTO A MATRIX TO OBTAIN DISCRETE SHELF-STABLE PARTICLES | GENERAL MILLS, INC. (US) | 2000-04-20 | — | — | WO | claimed |
| EP-0935523-A4 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | GEN MILLS INC (US) | 1999-12-29 | — | — | EP | claimed |
| EP-0935523-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | GENERAL MILLS, INC. (US) | 1999-08-18 | — | — | EP | claimed |
| WO-1998018610-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | LENGERICH BERNHARD H VAN (US) | 1998-05-07 | — | — | WO | claimed |
| EP-0428296-B1 | Pharmaceutical compositions for treating gastrointestinal distress | MCNEIL PPC INC (US) | 1994-06-08 | — | — | EP | claimed |
| EP-0465234-A1 | Pharmaceutical compositions and methods for alleviating gastrointestinal distress symptoms induced by nonsteroidal anti-inflammatory drugs | McNEIL-PPC, INC. (US) | 1992-01-08 | — | — | EP | claimed |
| EP-0428296-A2 | Pharmaceutical compositions for treating gastrointestinal distress | McNEIL-PPC, INC. (US) | 1991-05-22 | — | — | EP | claimed |
| US-4384000-A | Method for treatment of various dermatological conditions | LANIER EARL W | 1983-05-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11033572-B2 | Molecular adjuvants for enhanced cytosolic delivery of active agents | TLR9, PLA2G4C, STING1 | OPRM1 4040/4885KCNA3 4725/4885OPRD1 4420/4885 |
| US-20230248734-A1 | ANTIVIRAL COMPOSITION OBTAINED THROUGH DRUG REPOSITIONING | SARS1, EIF2AK2, ACE2 | OPRM1 2265/4885KCNA3 4221/4885OPRD1 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.